Harnessing a novel CRISPR nuclease for programmable counterselection in human cells

Projektinformationen

CRISPR-SELECT

ID Finanzhilfevereinbarung: 101158249

DOI

10.3030/101158249

Projekt abgeschlossen

EK-Unterschriftsdatum 6 Februar 2024

Startdatum 1 April 2024

Enddatum 30 September 2025

Finanziert unter

• European Research Council (ERC)

Gesamtkosten

Keine Daten

EU-Beitrag

€ 150 000,00

Koordiniert durch

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

Periodic Reporting for period 1 - CRISPR-SELECT (Harnessing a novel CRISPR nuclease for programmable counterselection in human cells)

Berichtszeitraum: 2024-04-01 bis 2025-09-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

CRISPR technologies and their creation of defined DNA edits in virtually any organism are revolutionizing medicine, agriculture, basic research, and biotechnology. However, editing is often inefficient, requiring additional and often laborious screening steps. My group’s recent work, which stemmed from my ERC Consolidator Award, offers a unique opportunity: achieving the first means to select for a desired gene edit in eukaryotic cells. Such a capability could relieve this pain point, becoming a highly desirable approach across many applications of genome editing. Through this project, we will achieve a proof-of-concept demonstration and lay the groundwork for commercialization and widespread adoption.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The project achieved the proof-of-principle demonstration of enriching gene edits in human cells through two modalities: indel formation and prime editing. The resulting work is currently in submission as a revised manuscript.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Further IP was secured through a variant of the Cas12a2 nucleases called Cas12a3. Future implementation will require follow-on demonstrations, development of guide rules, and expansion to other cell lines and organisms, such as plants.